Kelun-Biotech has become the second drugmaker to bring a TROP2-directed antibody-drug conjugate to regulatory approval, getting a green light in China for sacituzumab tirumotecan (sac-TMT). The ...
© 2026 Forbes Digital Marketing Inc (FDMI). Forbes Advisor is operated by FDMI and is not controlled by Forbes Media LLC.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results